Table 1.
Sample | Complex glycans (%) |
Oligomannose (%) | |||||
---|---|---|---|---|---|---|---|
Predominant glycan |
Terminal Sialylation |
Terminal Galactosylation | Terminal Fucosylation | ||||
GO | GOF | α2–3 | Total | ||||
Patient 1, dimeric IgA | 12.2 | 12.0 | 1.4 | 14.8 | 26.2 | 56.9 | – |
Patient 1, monomeric IgA | 18.5 | 5.6 | 2.9 | 27.4 | 36.2 | 56.6 | – |
Patient 2, dimeric IgA | 12.5 | 20.7 | 6.7 | 17.3 | 17.4 | 55.5 | – |
Patient 2, monomeric IgA | 18.8 | 17.0 | 5.7 | 10.5 | 16.0 | 56.4 | – |
3.1 IgA1 | 43.7 | – | 30.4 | 51.0 | 0.5 | 1.1 | 2.1 |
3.1 IgA2 | 53.3 | – | 11.2 | 22.1 | 1.2 | 12.1 | 1.8 |
3.1 IgG1 | 40.3 | 1.2 | – | – | 57.2 | 58.6 | – |
Different recombinant isotypes of mAb 3.1 as well as IgA from two adult male Caucasians purified from saliva were run on SDS-PAGE to separate dimeric from monomeric forms. The corresponding gel bands were excised, and the N-linked glycans were released from the protein by PNGase digestion and further subjected to digestion with specific glycosylases (EndoH, α2–3,6,8 neuraminidase, β1,4-galactosidase, α-L-fucosidase, β-N-acetylglucosaminidase, α(1-2,3,6)-mannosidase). Differential analysis by HILIC-UPLC was then performed, and the percentages were determined by the sum of the areas under the specific peaks over the area under all peaks.